CHICAGO--(BUSINESS WIRE)--CytoCore (OTCBB:CYCR.OB), the biopharmaceutical research and medical device company for early detection and treatment of reproductive-tract cancers, today announced that it has completed the process of demonstrating conformity of the e2 Collector™ cervical cell collection device to the requirements of the Medical Device Directive for sales into the European Union.
